Antibiotic Resistance Market - By Disease (cUTI, cIAI, BSI), Pathogen (E. coli, K. pneumoniae), Drug Class (Oxazolidinones, Cephalosporin), Mechanism of Action (Cell Wall, Protein Synthesis Inhibitors), Distribution Channel, Global Forecast, 2023-2032

Antibiotic Resistance Market - By Disease (cUTI, cIAI, BSI), Pathogen (E. coli, K. pneumoniae), Drug Class (Oxazolidinones, Cephalosporin), Mechanism of Action (Cell Wall, Protein Synthesis Inhibitors), Distribution Channel, Global Forecast, 2023-2032

Antibiotic Resistance Market Size

Antibiotic Resistance Market size is valued to be USD 8.2 billion in 2022 and is projected to grow at CAGR of 5.3% and reach USD 13.6 billion by 2032. Some of the major factors driving the growth of this market are increasing incidence of antibiotic resistant infections, growing need for new antibiotic therapies, increasing investment in antibiotic research and development, and increasing global public health concern and awareness.
 

Antibiotic resistance is an ability of bacteria or other microorganisms to resist the effects of antibiotics that were once effective in treating infections caused by them. This resistance develops when bacteria experience genetic alterations or mutations that enable them to survive and thrive even in the presence of antibiotics, reducing or eliminating the effectiveness of the medications. As a result, infections caused by these resistant bacteria become more difficult to treat, leading to prolonged illness, increased treatment costs, and potentially higher mortality rates.
 

COVID-19 Impact

During the initial stages of the pandemic, there was an increased demand and use of antibiotics to treat secondary bacterial infections among the COVID-19 patients. The heightened use had potentially contribute to the development of antibiotic resistance. Further, the increased awareness among the public, healthcare professionals, and policymakers had resulted into a better understanding about the risks associated with antibiotic resistance and the need for adequate and responsible antibiotic usage.
 

The pandemic underscored the importance of antimicrobial stewardship programs, which promote the proper use of antibiotics and helping in overcoming the challenges caused by antibiotic resistant infections. Healthcare systems prioritized such programs to ensure that antibiotics are used only administered when required and with adequate doses to prevent the spread of drug-resistant infections. The pandemic increased public awareness of infectious diseases leading to better understanding of the consequences of antibiotic resistance and the importance of responsible antibiotic use. Overall, the pandemic had a positive impact on the global market demand.
 

Antibiotic Resistance Market Driving Factors

Antibiotic resistance has become a serious health concern that requires a multifaceted approach that includes responsible antibiotic use, infection prevention and control measures, the development of new antibiotics and treatment strategies. The rising prevalence of antibiotic resistant infections caused by bacteria such as E. coli and Staphylococcus aureus is majorly contributing to the growth of this market. Due to the increasing number of infectious diseases the demand for antibiotic therapies is growing which is boosting the growth of this market. Hospital-acquired infections, often caused by drug-resistant bacteria, increase healthcare costs, patient morbidity, and mortality rates. The rise of these infections emphasizes the need for infection prevention and control measures.
 

Antibiotic Resistance Disease Market Analysis

Based on disease, the antibiotic resistance market is categorized into complicated urinary tract infections (cUTI), complicated intra-abdominal infections (cIAI), bloodstream infection (BSI), acute bacterial skin and skin-structure infection (ABSSSI), community-acquired bacterial pneumonia (CABP), clostridium difficile infections (CDI), and hospital-acquired bacterial pneumonia (HABP). In 2022, the complicated urinary tract infections segment held the highest market share of 24.7%. The factors contributing to the growth are increasing incidence of cUTI, strong product pipeline, and increasing prevalence of underlying medical conditions like diabetes and kidney diseases which are more likely to develop cUTI. Due to the severity and complication of cUTIs, such patients require the use antibiotics with broader spectrum coverage to target a wider range of potential pathogens, including drug-resistant strains.
 

Based on pathogen, the antibiotic resistance market is segmented into E. coli, K. pneumoniae, P. aeruginosa, S. aureus, Baumannii, S. pneumoniae, H. influenzae, C. difficile, and E. faecium. Among the pathogens, the E. coli segment accounted for highest market share and was valued at USD 2.2 billion in 2022. K. pneumoniae held the second highest market share of 21.4%. This is due to the high incidence rate antibiotic resistant infections caused by Enterobacteriaceae which includes E. coli and K. pneumoniae. According to the National Institutes of Health, it is estimated that each year 140,000 health care associated Enterobacteriaceae infections occur in the U.S. During the forecast period, C. difficile is expected to grow at fastest CAGR followed by P. aeruginosa strains which is responsible for high morbidity and mortality rate leading to prolonged treatment and higher costs treatment cost compared to other infections.
 

Based on drug class, the antibiotic resistance market is classified into oxazolidinones, cephalosporin, lipoglycopeptides, combination therapies, tetracyclines, and other drug classes. The oxazolidinones segment held largest business share of 14% and is expected to grow at CAGR of 5.1% over the coming years. Oxazolidinones, especially Linezolid, which has strong activity against both aerobic and anaerobic of Gram-positive bacteria, including those that are resistant to multiple other classes of antibiotics. They are bacteriostatic antibiotics, that means they inhibit bacterial growth and does not kill the bacteria directly. The bacterial proliferation can be prevented by using such mode of action. During the forecast period, combination therapies segment is anticipated to witness growth at CAGR of 8% due to the growing burden of antibiotic-resistant Gram-negative infections.
 

Based on the mechanism of action, the antibiotic resistance market is segmented into cell wall synthesis inhibitors, protein synthesis inhibitors, DNA synthesis inhibitors, RNA synthesis inhibitors, and other mechanism of actions. The cell wall synthesis inhibitors segment held highest market share and was valued to be USD 2.6 billion in 2022. They have broad spectrum activity against a broad range of bacteria, such as Gram-positive and some Gram-negative species which results in widespread use and higher prescription rates. The RNA synthesis inhibitors are expected to grow at fastest CAGR during the forecast period due to the unique mode of action by disrupting the transcription process and broad-spectrum activity.

Based on the distribution channel, the antibiotic resistance market is segmented into hospital, retail, and online pharmacies. In 2022, the hospital pharmacies segment accounted for highest revenue share of 54%. Hospital pharmacies often participate in antimicrobial stewardship programs ensuring that antibiotics are prescribed properly as per the clinical need, susceptibility data, and guidelines. The hospital pharmacies provide optimum dosing ensuring that antibiotics are dosed correctly based on patient condition. The online pharmacies segment is projected to grow at fastest CAGR during the forecast period as it offers convenience and accessibility. Some online pharmacies need valid prescription to order such antibiotics which is significantly reducing the overuse and misuse of antibiotics.
 

In 2022, the North American antibiotic resistance market is expected to reach USD 5.5 billion by 2032. The region has a relatively high prevalence of antibiotic resistant infections as the region has one of the highest rates of antibiotic consumption. Moreover, the increasing research and development activities related to antibiotics, increasing government support and fundings, and presence of key players operating in this market are expected to drive the growth of this market.
 

Antibiotic Resistance Market Share

The key players in the antibiotic resistance market are

• ACHAOGEN, INC.
• Basilea Pharmaceutica Ltd.
• MELINTA THERAPEUTICS
•  Tetraphase Pharmaceuticals, Inc.
• Theravance Biopharma
• WOCKHARDT
• Entasis therapeutics
• Paratek Pharmaceuticals
• Inc., Seres Therapeutics
• AbbVie, Inc.,
• Merck & Co. Inc.
• and Pfizer, Inc.

These companies are implementing several strategies such as collaborations, acquisitions, partnerships, mergers, and product launches to maintain a competitive edge in the industry.
 

Antibiotic Resistance Industry News

• In February 2018, FDA approved AVYCAZ of AbbVie, Inc for the patients with Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia. This product launch helped the company to strengthen their portfolio and boost their revenue.
   
• In November 2019, Allergan plc, which is now a part of AbbVie, Inc. received the Qualified Infectious Disease Product (QIDP) designation and fast track designation for ATM-AVI (Aztreonam and Avibactam) for antibiotic-resistant gram-negative infections from U.S. FDA. This helped the company to enhance their position in global market.
   

The antibiotic resistance market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments

Click here to Buy Section of this Report

Market Size, By Disease

• Complicated urinary tract infections
• Complicated intra-abdominal infections
• Bloodstream infection
• Acute bacterial skin and skin-structure infection
• Community-acquired bacterial pneumonia
• Clostridium difficile infections
• Hospital-acquired bacterial pneumonia

Market Size, By Pathogen

• E. coli
• K. pneumoniae
• P. aeruginosa
• S. aureus
• Baumannii
• S. pneumoniae
• H. influenzae
• C. difficile
• E. faecium

Market Size, By Drug Class

• Oxazolidinones
• Cephalosporin
• Lipoglycopeptides
• Combination therapies
• Tetracyclines
• Other drug classes

Market Size, By Mechanism of Action

• Cell wall synthesis inhibitors
• Protein synthesis inhibitors
• DNA synthesis inhibitors
• RNA synthesis inhibitors
• Other mechanism of actions

Market Size, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Switzerland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East & Africa